Low-Invasive Biomarkers of Canine Mammary Tumours

Abstract

Canine mammary tumours (CMTs) are the most common type of tumours in older bitches. An early, precise and low-invasive diagnosis is essential, due to some CMTs being malignant and having a poor prognosis. Fine needle aspiration cytology (FNAC) and blood tests are both low-invasive diagnostic methods that have been used in veterinary medicine. However, the perfect biomarkers should be identified to diagnose and evaluate the prognosis of CMTs. This review focuses on biomarkers that can be tested by FNA or blood samples based on current literature. Until now, the most studied biomarkers of FNAC, such as Ki-67, human epidermal growth factor receptor 2 (HER-2), oestrogen receptor (ER), progesterone receptor (PR), P53, E-cadherin and cyclooxygenase-2 (COX-2). Some common blood biomarkers that have been widely studied include lactate dehydrogenase (LDH), C-reactive protein (CRP), carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA). The novel biomarkers will also be mentioned: cancer stem cells (CSCs), circulating tumour cells (CTCs), miRNAs and circulating cell-free DNA (cfDNA); they are all useful markers. Copper ion and serum ferritin (SF) are good markers of human breast cancer; they may be candidates of CMTs biomarkers, too. In conclusion, many biomarkers are suitable for diagnosing and/or prognosing CMTs; combining a couple of them can increase the specificity; more detailed research should be done.

Keywords: biomarkers; blood biomarkers; canine mammary tumours; fine needle aspiration cytology; low‐invasive.

FIGURE 1

Categories of tumour diagnostic biomarkers. CSC, cancer stem cell; CTC, circulating tumour cell; ER, oestrogen receptor; HER‐2, human epidermal growth factor receptor 2; LDH, lactate dehydrogenase; PR, progesterone receptor.